Abstract
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been reported in patients with secondary chromosome abnormalities. We report a patient who developed AML during imatinib treatment of Ph-positive CML despite a cytogenetic response and absence of secondary chromosome abnormalities. Thus, development of AML as a rare event in CML patients with cytogenetic responses to imatinib therapy does not depend on the development of secondary cytogenetic abnormalities.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Base Sequence
-
Benzamides
-
DNA Primers
-
DNA, Complementary
-
Female
-
Humans
-
Imatinib Mesylate
-
In Situ Hybridization, Fluorescence
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myeloid, Acute / chemically induced*
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / genetics
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Benzamides
-
DNA Primers
-
DNA, Complementary
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate